No abstract available.
Quinolones* ; Vibrio vulnificus* ; Vibrio*

No abstract available.
Abscess* ; Bacteria, Aerobic* ; Quinolones* ; Virulence*

Sexual dysfunction is a common side effect in patients treated with antipsychotics but significant differences exist across different compounds. We report hypersexuality symptoms in two female patients with schizophrenia who were receiving treatment with aripiprazole. The patients experienced more frequent sexual desire and greater sexual preoccupation after taking aripiprazole. We discuss the potential neuro-chemical mechanisms for this and argue that aripiprazole's unique pharmacological profile, partial agonism with high affinity at dopamine D2-receptor, may have contributed to the development of these symptoms.
Antipsychotic Agents ; Dopamine ; Felodipine ; Female ; Humans ; Piperazines ; Quinolones ; Schizophrenia ; Aripiprazole

OBJECTIVE: This study aimed to assess the efficacy of aripiprazole for the management of cognitive impairments and hyperprolactinemia in patients with schizophrenia on a stable dose of risperidone. METHODS: Thirty-five subjects stabilized on risperidone (3-6 mg/day) for a minimum of 3 months were enrolled in a double-blind, placebo-controlled phase for 12 weeks and an open-label phase for another 12 weeks. Subjects were randomly assigned to receive 10 mg/day aripiprazole (n=17) or placebo (n=18). Over the following 12 weeks, the the aripiprazole group received a flexible dose of aripiprazole while tapering risperidone. At baseline, week 12, and week 24, subjects were evaluated using the Positive and Negative Syndrome Scale (PANSS), Extrapyramidal Syndrome Rating Scale (ESRS), and standardized neuropsychological assessments. Serum prolactin levels were checked at baseline, week 1, week 2, and week 24. RESULTS: The mean change in total PANSS and cognitive function test scores between baseline and endpoint were similar in the aripiprazole and placebo groups. Scores on the ESRS and negative subscale of PANSS differed significantly between groups in both phases of the study (p<0.05), indicating a positive effect of aripiprazole. Compared with placebo, aripiprazole significantly reduced mean baseline serum prolactin levels within 1 week (p=0.015). CONCLUSION: Adjunctive treatment with and switching to aripiprazole were not associated with improved cognitive function in patients with schizophrenia receiving risperidone; however, aripiprazole treatment decreased negative symptoms and risperidone-induced motor side effects and lowered serum prolactin levels.
Cognition ; Humans ; Hyperprolactinemia ; Piperazines ; Prolactin ; Quinolones ; Risperidone ; Schizophrenia ; Aripiprazole

No Abstract Available.
Anti-Infective Agents* ; Enterohemorrhagic Escherichia coli* ; Quinolones* ; Shiga Toxins*

OBJECTIVE: We examined the effect of long-term aripiprazole therapy on social functioning in Korean patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. METHODS: In this 52-week open-label, multicenter, single-arm study, 300 Korean patients with schizophrenia were treated with aripiprazole 10-30 mg/day after administration of 15 mg/day during the first 2 weeks. The primary efficacy measure was the Korean-Social Functioning Scale (SFS-K), and the secondary efficacy measures were the Emotion Assessment, and the Positive and Negative Syndrome Scale (PANSS) score and the Clinical Global Impression - Severity of Illness (CGI-S) to investigate for correlation between social functioning and clinical symptoms. RESULTS: At week 52, there were significant improvements in all the areas of the SFS-K. There was generally no difference in the change of social functioning between patients in the first episode and patients having previous episodes. Significant improvements were also observed in negative emotion and emotional control. Statistically significant correlation between the SFS-K and the PANSS score was observed at week 52. CONCLUSION: The present study showed that long-term treatment with aripiprazole contributed to significant improvement in social functioning in patients with schizophrenia in the long-term treatment. This improvement of social functioning was modestly associated with clinical improvement of symptoms. The results suggest that long-term aripiprazole therapy could be effective not only in treating clinical symptoms, but also in improving social functioning in patients with schizophrenia-spectrum disorder.
Humans ; Piperazines ; Prospective Studies ; Psychotic Disorders ; Quinolones ; Schizophrenia ; Aripiprazole

BACKGROUND: Moxifloxacin is an 8-methoxyquinolone compound which has been shown to have the best activity of the quinolones against M. tuberculosis but there is no literature showing the rate of cross-resistance between moxifloxacin and the other quinolones such as ofloxacin. Therefore, we tested the activity of moxifloxacin against ofloxacin resistant M. tuberculosis by a study of cross-resistance. METHODS: We tested MIC's of moxifloxacin and ofloxacin by proportion method against 34 M. tuberculosis isolates showing resistance against ofloxacin at 2.5microgram/ml concentration and 13 ofloxacin susceptible isolates from specimens submitted to clinical laboratory of National Masan Hospital from March 2003 to March 2004. RESULTS: For ofloxacin susceptible isolates, MIC(50) and MIC(90) of ofloxacin were all 1.25 microgram/ml, and MIC(50) and MIC(90) of moxifloxacin were 0.31 microgram/ml and 0.63microgram/ml respectively. For ofloxacin resistant isolates, MIC(50) of ofloxacin was over 10microgram/ml and MIC(50) of moxifloxacin was 5microgram/ml,MIC(90) of ofloxacin and moxifloxacin were all over 10microgram/ml. The rate of cross-resistance between the two was 67.6%(23/34) at 2.5microgram/ml concentration. CONCLUSIONS: Moxifloxacin showed activity against 82.4%(28/34) of ofloxacin resistant M. tuberculosis at 10microgram/ml, but more studies are needed so that moxifloxacin will be used for patient with multi-drug resistant tuberculosis including ofloxacin resistance.
Humans ; Mycobacterium tuberculosis* ; Mycobacterium* ; Ofloxacin* ; Quinolones ; Tuberculosis ; Tuberculosis, Multidrug-Resistant

BACKGROUND/AIMS: Sulglycotide is a non-systemic drug, used in the treatment of peptic ulcer and gastritis. The aim of this study was to assess the therapeutic effect and safety of Gliptide (sulglycotide 200 mg) in comparison with Mucosta (rebamipide 100 mg) for treatment of gastritis. MATERIALS AND METHODS: Two hundred and three symptomatic patients with erosive gastritis at endoscopy were randomized to receive sulglycotide or rebamipide for four weeks. Therapeutic effects of the drugs for gastritis were evaluated by follow up endoscopic scoring systems and clinical symptoms. We also sought possible adverse effects of the two drugs. RESULTS: Gliptide (sulglycotide) and Mucosta (rebamipide) treatment in symptomatic gastritis resulted in endoscopic improvement rates of gastritis by 52.0%, 60.6% in intention-to-treat (ITT) analysis, 53.4%, 61.1% in per protocol (PP) analysis, which means therapeutic effects was not different between the two groups. The symptom improvement rates in the sulglycotide and rebamipide treated group were 57.3%, 57.5% in ITT analysis, 54.7%, 58.8% in PP analysis, which mean statistically no significant difference between the two groups. Endoscopic findings such as cure rates of erosion, edema, improvement rates of redness, hemorrhage were not significantly different between the two groups. No statistical significant differences were observed for adverse events between the two groups. The results of 95% CIs for the difference in endoscopic improvement rate and symptom improvement rate met the criteria for the non-inferiority of sulglycotide to rebamipide. CONCLUSIONS: These results demonstrate that Gliptide (sulglycotide) was not inferior to Mucosta (rebamipide) for endoscopic and symptomatic improvements for symptomatic erosive gastritis.
Alanine ; Edema ; Endoscopy ; Follow-Up Studies ; Gastritis ; Hemorrhage ; Humans ; Peptic Ulcer ; Quinolones ; Sialoglycoproteins

OBJECTIVES: The purpose of this study was to investigate the efficacy and predictors of response to aripiprazole treatment in acute schizophrenic patients. We investigated whether baseline agitation level influences the treatment response, and examined the effects of oral aripiprazole in acute patients with schizophrenia experiencing either higher or lower levels of agitation. METHODS: In this 8-week non-comparative clinical trial, 19 patients with a DSM-IV diagnosis of acute schizophrenia were enrolled. They were divided into groups experiencing higher or lower agitation at baseline. PANSS scores, CGI scores, GAF scores, and PANSS-EC score were used for efficacy assessments. RESULTS: 63.2% of patients completed the study. The average dosage of aripiprazole was 26.2+/-4.8 mg. Treatment with aripiprazole resulted in significant improvement from baseline in all efficacy measures. In both the higher and lower groups, aripiprazole treatment produced significantly lower PANSS total and PANSS-EC scores, compare with baseline. Moreover, these significant improvements were sustained throughout a 8-week period. A shorter duration of the present episode is associated with a better clinical response. Extrapyramidal symptoms were observed in 36.8% of patients; however, the side effects did not influence the treatment response. CONCLUSION: High doses of aripiprazole significantly improved acute symptoms of schizophrenia irrespective to baseline agitation level, without any significant adverse event. These results suggest that aripiprazole is an effective and safe treatment option for patients with acute schizophrenia who manifest agitation symptoms.
Diagnostic and Statistical Manual of Mental Disorders ; Dihydroergotamine ; Humans ; Piperazines ; Quinolones ; Schizophrenia ; Aripiprazole

OBJECTIVE: To determine if the maintenance effectiveness and tolerability of aripiprazole demonstrated in a 12-week study were maintained in an extension phase (up to 26 weeks). METHODS: This study was the extension of our switching study from other antipsychotics to aripiprazole in symptomatically stable patients with schizophrenia or schizoaffective disorder. All the patients were randomly assigned to the aripiprazole group or the non-aripiprazole group. The effectiveness analysis consisted of the comparison of the upper bound of the 95% confidence interval (CI) of the mean Clinical Global Impression-Improvement (CGI-I) score to 4 (no change) at the end of the study. RESULTS: At the baseline, the aripiprazole group (n=135) and the non-aripiprazole group (n=31) were comparable with respect to their mean ages, gender distribution, baseline Positive and Negative Syndrome Scale scores, and Clinical Global Impression-Severity (CGI-S) scores. The study showed that the mean CGI-I score was 2.92 (95% CI: 2.72-3.12) in the aripiprazole group and 2.81 (95% CI: 2.35-3.26) in the non-aripiprazole group at 26 weeks. In the aripiprazole group, the remission rates at 12 and 26 weeks were 74.8% and 72.6%, respectively, and 80.2% of the patients with remission at 12 weeks maintained their remission state until the end of the study. About one-fourth of the patients in the aripiprazole group reported one or more spontaneous treatment-emergent adverse events, such as insomnia, headache, and nausea. CONCLUSION: This study suggested that most clinically stable outpatients with schizophrenia maintain their remission states after being switched to aripiprazole, without serious symptom aggravation and adverse events over a course of 26 weeks.
Antipsychotic Agents ; Headache ; Humans ; Nausea ; Outpatients ; Piperazines ; Psychotic Disorders ; Quinolones ; Schizophrenia ; Sleep Initiation and Maintenance Disorders ; Aripiprazole